Mantle Cell Lymphoma | Tumor

CURE’s mantle cell lymphoma (MCL) page features the latest cancer news and updates on mantle cell lymphoma Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in mantle cell lymphoma.

Managing Mantle Cell Lymphoma (MCL) after Relapsed on First Treatment

An interview with Dr. Luhua (Michael) Wang, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicine, MD Anderson Cancer Center

Keep Inspiring

Don’t let your disease define you

Experimental Lymphoma Drug Shows ‘Robust Clinical Activity,’ Researchers Say

February 25th 2022, 2:00pm

Article

Treatment with TRPH-222 led to lasting responses in certain patients with relapsed/refractory B-cell non-Hodgkin lymphomas, warranting a larger investigation into the drug, according to the researchers.

My Oncologist Gave Me a Pseudo-Medication Taper That Made Me Feel Like I Was Losing Control

February 16th 2022, 6:00pm

Article

In the midst of my treatment for mantle cell lymphoma, I had to suffer through the feeling of wanting to crawl out of my own skin when my oncologist gave me a medication tapering plan that was not gradual enough.

Decades of MCL Treatment Advancements a ‘Godsend’ for Patients

February 14th 2022, 8:00pm

Article

From the use of BTK inhibitors to maintenance therapy, an expert highlights how the treatment landscape of mantle cell lymphoma has drastically changed for the better in recent decades.

Supportive Care and Palliative Care May Improve Outcomes in Patients Receiving CAR-T Cell Therapy

February 14th 2022, 4:00pm

Article

Supportive care should be implemented promptly after patients receive CAR-T cell therapy, but as one expert notes, patients with cancer are often referred for this care too late.

Clinical Trial Testing Effectiveness of LOXO-305 in Mantle Cell Lymphoma Now Open to Patients

February 9th 2022, 10:00pm

Article

A phase 3 trial evaluating the safety and efficacy of the BTK inhibitor LOXO-305 in patients with previously treated mantle cell lymphoma is now open to patients across more than a dozen states.

Prophylactic Monoclonal Antibodies Recommended to Protect Certain Patients With Cancer From COVID-19

January 11th 2022, 8:30pm

Article

The National Comprehensive Cancer Network now recommends prophylactic monoclonal antibodies for immunosuppressed individuals, such as certain patients with cancer.

Third Full Dose of COVID-19 Vaccine Increases Antibody Response in Patients with Blood Cancers

December 23rd 2021, 8:00pm

Article

New findings show that 43% of patients with certain blood cancers produced COVID-19 antibodies after receiving a third full dose of the mRNA vaccine.

Side Effects, Costs Can Be ‘Game Changers’ in Deciding MCL Treatment

November 19th 2021, 10:00pm

Article

With three BTK inhibitors approved for treatment of mantle cell lymphoma, patients and providers should consider side effects and insurance coverage before deciding on a drug.

FDA Will Review New Drug to Treat Non-Hodgkin Lymphoma

November 1st 2021, 9:00pm

Article

The Food and Drug Administration will review parsaclisib for the treatment of patients with follicular lymphoma, marginal zone lymphoma and mantle cell lymphoma.

'The Future is Promising' For The Treatment of a Subtype of Non-Hodgkin Lymphoma

October 18th 2021, 1:00pm

Article

More selective BTK inhibitors like Brukinsa may give patients with mantle cell lymphoma who progressed on prior therapies another option with potentially fewer and more manageable side effects.